Loading
Pioneer of cancer genome sequencing and mutational signatures; led the Cancer Genome Project and formerly directed the Sanger Institute.
Michael Stratton is a senior group leader at the Wellcome Sanger Institute and served as its Director from 2010 until 2023. He led the Cancer Genome Project and was a founder of the International Cancer Genome Consortium, and his group established the concept of mutational signatures in human cancer. His work has defined much of the modern understanding of somatic mutation in cancer.
| Title | Journal | Year |
|---|---|---|
| Landscape of somatic mutations in 560 breast cancer whole-genome sequences | Nature | 2016 |
| The cancer genome | Nature | 2009 |
| Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | Nature Genetics | 2015 |
Shares Wellcome Sanger Institute and the tag clinician-scientist.
Shares the tags clinician-scientist, cancer genomics.
Shares the tags clinician-scientist, cancer genomics.
Shares Ageing tissue and clonal fields: cancer as a disease of old tissue, Driver and passenger mutations: the refined somatic mutation theory, Mutational signature, Somatic mutation theory of cancer.
Shares Driver and passenger mutations: the refined somatic mutation theory, Mutational signature, Somatic mutation theory of cancer.
Shares Mutational signature, Somatic mutation theory of cancer.
Shares Aneuploidy and chromosomal instability as the cause of cancer, Mutational signature.